N/A N=161 Intermittent Versus Continuous Pulse Oximetry Monitoring of Infants Admitted for Bronchiolitis
Bronchiolitis · Hypoxia
Primary: Length of Stay in the Hospital — 38.7; 39.5 hours — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=304 The Bronchiolitis Follow-up Intervention Trial
Bronchiolitis
Primary: Parental Anxiety — 4.2; 3.9 points on a scale
N/A N=48 Cohort Isolation and Cross-infection in Bronchiolitis
Bronchiolitis
Primary: Duration of Hospital Stay — 3.9; 2.1 days
N/A N=228 Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filters
Bronchiolitis
Primary: Number of Caregiver-reported Symptom-free Days (SFDs) — 118.01; 112.60 Days — p=0.537
N/A N=32 Heated Humidified Oxygen Compared to Dry Oxygen Therapy in Children With Bronchiolitis
Bronchiolitis · Hypoxemia
Primary: Change in Respiratory Distress Assessment Instrument (RDAI) From Baseline. — 4.69; 2.69; 4.27; 3 units on a scale
N/A N=141 Trial of Montelukast for Treatment of Acute Bronchiolitis
Bronchiolitis
Primary: Duration of Cough — 13; 11 days
N/A N=59 Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
Bronchiolitis · Respiratory Syncytial Virus Infections
Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020
Phase 4 N=64 Nebulized 3% Hypertonic Saline Solution Treatment of Bronchiolitis in Infants
Bronchiolitis · Wheezing
Primary: Score Respiratory Distress — 8; 8; 6; 8 units on a scale
N/A N=103 The Effectiveness of AAD and IPV to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis.
Bronchiolitis
Primary: Length of Hospital Stay — 3.5; 3.6; 4.5 days
N/A N=227 A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis
Bronchiolitis
Primary: Length of Stay in the Study-LOS--Intention to Treat Analysis — 2.1; 2.1 Days — p=0.73
N/A N=152 Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
Bronchiolitis · Bronchiolitis, Viral · RSV Infection
Primary: The Number of Sampling Visits on Which Participants Are Willing to Undergo Nasosorption and/or NPA Sampling — 124; 60; 0; 0 Sampling visits
Phase 3 N=72 Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients
Bronchiolitis
Primary: Change in Modified Wood's Clinical Asthma Score (M-WCAS) From Baseline to 240 Minutes — 1.84; .031 units on a scale — p=<0.05
Phase 2 N=40 Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis
RSV Bronchiolitis
Primary: IL-8 Concentrations — 12,795; 14,676 Pg/ml — p=0.6
Phase 4 N=62 Hypertonic Saline for Acute Bronchiolitis
Bronchiolitis, Viral · Saline Solution, Hypertonic
Primary: Respiratory Assessment Change Score (RACS) — -1.5; -4 units on a scale — p=0.01
Phase 3 N=200 Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II
Respiratory Syncytial Virus, Bronchiolitis
Primary: Number of Participants Who Experienced the Occurrence of a Third Episode of Post-RSV Wheezing (Recurrent Wheeze) — 45; 33 Participants — p=0.08
Phase 4 N=17 Bronchodilator Responsiveness in Obliterative Bronchiolitis
Obliterative Bronchiolitis
Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change
Phase 4 N=50 Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
Hematological Malignancies
Primary: Occurrences of Pneumonia — 4; 3 Participants
N/A N=100 Efficacy of Nebulized Hypertonic Saline in the Treatment of Acute Bronchiolitis
Bronchiolitis
Primary: Hospitalization Days — 5.8; 5.47 days
N/A N=2,401 A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age
Respiratory Syncytial Virus
Primary: Incidence Rates of First Episode of Respiratory Syncytial Virus (RSV) Respiratory Tract Infection (RTI) [Period 1] — 7.93 Cases per 100 person-years
Phase 4 N=100 Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Bronchiolitis.
Bronchiolitis
Primary: Mean Change in Clinical Severity Score — 2.26; 3.57 units on a scale — p=<0.05
Phase 2 N=46 Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis
Bronchiolitis
Primary: Respiratory Rate — -3.7; -1.7 Percentage change in respiratory rate
Phase 3 N=447 Nebulized Hypertonic Saline for Bronchiolitis
Bronchiolitis
Primary: Admission Rate — 55; 76; 141; 107 participants
N/A N=52 Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis
Acute Bronchiolitis
Primary: Respiratory Assessment Change Score (RACS) — 1.68; 1.70 score on a scale
Phase 2 N=44 Respiratory Syncytial Virus - RSV Protocol
Bone Marrow Transplant Infection · Infection in Marrow Transplant Recipients · Respiratory Syncytial Virus Infections
Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants
N/A N=343 Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)
Respiratory Syncytial Virus Bronchiolitis
Primary: Percentage of Participants With Asthma at 6 Years of Age: Overall and by Prognostic Factor — 6.1; 11.2; 3.1; 9.6 percentage of participants
Phase 4 N=80 Effect of OM-85 BV on Wheezing Related Morbidity in Children With Recurrent Wheezing
Asthma
Primary: Mean Rate of Wheezing Attacks — 3.57; 5.72 wheezing attacks/per patient — p=0.05
N/A N=58 The Development of a Human Model of Respiratory Syncytial Virus Infection
Respiratory Syncytial Virus Infections · Respiratory Viral Infections
Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants
Phase 2 N=180 Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Primary: Time for Viral Load to Drop Below Assay Quantification Limit (BQL) (Plaque Assay Analysis) — 46.1; 14.2; 5.1; 5.1 hours — p=<0.001
Phase 2 N=48 Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children
Respiratory Syncytial Virus
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0 participants
N/A N=197 Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With Suspected Infection of the Lungs, in Spain.
Infections, Streptococcal
Primary: Number of Subjects With Bacterial Aetiology, Assessed by Culture Growth, From Bronchoalveolar Lavage (BAL) Fluid Samples — 141; 49; 1; 58 Participants